Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors.

Abstract:

:In order to compare in vivo metabolism between malignant gliomas and normal brain, (13)C magnetic resonance (MR) spectroscopic imaging data were acquired from rats with human glioblastoma xenografts (U-251 MG and U-87 MG) and normal rats, following injection of hyperpolarized [1-(13)C]-pyruvate. The median signal-to-noise ratio (SNR) of lactate, pyruvate, and total observed carbon-13 resonances, as well as their relative ratios, were calculated from voxels containing Gadolinium-enhanced tissue in T(1) postcontrast images for rats with tumors and from normal brain tissue for control rats. [1-(13)C]-labeled pyruvate and its metabolic product, [1-(13)C]-lactate, demonstrated significantly higher SNR in the tumor compared with normal brain tissue. Statistical tests showed significant differences in all parameters (P < .0004) between the malignant glioma tissue and normal brain. The SNR of lactate, pyruvate, and total carbon was observed to be different between the U-251 MG and U-87 MG models, which is consistent with inherent differences in the molecular characteristics of these tumors. These results suggest that hyperpolarized MR metabolic imaging may be valuable for assessing prognosis and monitoring response to therapy for patients with brain tumors.

journal_name

Neuro Oncol

journal_title

Neuro-oncology

authors

Park I,Larson PE,Zierhut ML,Hu S,Bok R,Ozawa T,Kurhanewicz J,Vigneron DB,Vandenberg SR,James CD,Nelson SJ

doi

10.1093/neuonc/nop043

subject

Has Abstract

pub_date

2010-02-01 00:00:00

pages

133-44

issue

2

eissn

1522-8517

issn

1523-5866

pii

nop043

journal_volume

12

pub_type

杂志文章
  • Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.

    abstract::Cytotoxic chemotherapy that induces lymphopenia is predicted to ablate the benefits of active antitumor immunization. Temozolomide is an effective chemotherapeutic agent for patients with glioblastoma multiforme, but it induces significant lymphopenia. Although there is monthly fluctuation of the white blood cell coun...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2007-046

    authors: Heimberger AB,Sun W,Hussain SF,Dey M,Crutcher L,Aldape K,Gilbert M,Hassenbusch SJ,Sawaya R,Schmittling B,Archer GE,Mitchell DA,Bigner DD,Sampson JH

    更新日期:2008-02-01 00:00:00

  • A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.

    abstract::The 2007 World Health Organization (WHO) classification of brain tumors did not use molecular abnormalities as diagnostic criteria. Studies have shown that genotyping allows a better prognostic classification of diffuse glioma with improved treatment selection. This has resulted in a major revision of the WHO classifi...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/now277

    authors: van den Bent MJ,Weller M,Wen PY,Kros JM,Aldape K,Chang S

    更新日期:2017-05-01 00:00:00

  • PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.

    abstract::We investigated the activation of platelet-derived growth factor (PDGF) receptor A (PDGFRA), PDGF receptor B (PDGFRB), epidermal growth factor receptor (EGFR), and their downstream pathways in malignant peripheral nerve sheath tumors (MPNSTs). PDGFRA, PDGFRB, and EGFR were immunohistochemically, biochemically, cytogen...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2009-003

    authors: Perrone F,Da Riva L,Orsenigo M,Losa M,Jocollè G,Millefanti C,Pastore E,Gronchi A,Pierotti MA,Pilotti S

    更新日期:2009-12-01 00:00:00

  • Symptom-based interventions to promote quality survivorship.

    abstract::Survival alone is no longer an adequate outcome for persons with brain tumors; the quality of the survivorship experience should be viewed with equal importance. Symptom management is a significant component of quality survivorship care. Regardless of their histology, brain tumors and therapies used to treat them prod...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noy100

    authors: Amidei C

    更新日期:2018-11-09 00:00:00

  • Altered brain morphology after focal radiation reveals impact of off-target effects: implications for white matter development and neurogenesis.

    abstract:Background:Children with brain tumors treated with cranial radiation therapy (RT) often exhibit cognitive late effects, commonly associated with reduced white matter (WM) volume and decreased neurogenesis. The impact of radiation damage in particular regions or tissues on brain development as a whole has not been eluci...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nox211

    authors: Beera KG,Li YQ,Dazai J,Stewart J,Egan S,Ahmed M,Wong CS,Jaffray DA,Nieman BJ

    更新日期:2018-05-18 00:00:00

  • VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells.

    abstract:BACKGROUND:Malignant glioma is a common and lethal primary brain tumor in adults. Here we identified a novel oncoprotein, vesicle-associated membrane protein 8 (VAMP8), and investigated its roles in tumorigenisis and chemoresistance in glioma. METHODS:The expression of gene and protein were determined by quantitative P...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nou219

    authors: Chen Y,Meng D,Wang H,Sun R,Wang D,Wang S,Fan J,Zhao Y,Wang J,Yang S,Huai C,Song X,Qin R,Xu T,Yun D,Hu L,Yang J,Zhang X,Chen H,Chen J,Chen H,Lu D

    更新日期:2015-03-01 00:00:00

  • Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy.

    abstract::Angiogenesis is necessary for tumor growth beyond a volume of approximately 2 mm(3). This observation, along with the accessibility of tumor vessels to therapeutic targeting, has resulted in a research focus on inhibitors of angiogenesis. A number of endogenous inhibitors of angiogenesis are found in the body. Some of...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1215/S115285170400119X

    authors: Rege TA,Fears CY,Gladson CL

    更新日期:2005-04-01 00:00:00

  • Malignant pineal germ-cell tumors: an analysis of cases from three tumor registries.

    abstract::The exact incidence of pineal germ-cell tumors is largely unknown. The tumors are rare, and the number of patients with these tumors, as reported in clinical series, has been limited. The goal of this study was to describe pineal germ-cell tumors in a large number of patients, using data from available brain tumor dat...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2007-054

    authors: Villano JL,Propp JM,Porter KR,Stewart AK,Valyi-Nagy T,Li X,Engelhard HH,McCarthy BJ

    更新日期:2008-04-01 00:00:00

  • Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study.

    abstract::The Pediatric Oncology Group conducted a phase II study to evaluate the activity of carboplatin in children 5 years or younger with progressive optic pathway tumors (OPTs). Of the 51 patients accrued to this study, 1 was not eligible because the child was older than 6 years. Fifty patients were eligible and had either...

    journal_title:Neuro-oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1093/neuonc/2.4.213

    authors: Mahoney DH Jr,Cohen ME,Friedman HS,Kepner JL,Gemer L,Langston JW,James HE,Duffner PK,Kun LE

    更新日期:2000-10-01 00:00:00

  • Diffusion radiomics as a diagnostic model for atypical manifestation of primary central nervous system lymphoma: development and multicenter external validation.

    abstract:Background:Radiomics is a rapidly growing field in neuro-oncology, but studies have been limited to conventional MRI, and external validation is critically lacking. We evaluated technical feasibility, diagnostic performance, and generalizability of a diffusion radiomics model for identifying atypical primary central ne...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1093/neuonc/noy021

    authors: Kang D,Park JE,Kim YH,Kim JH,Oh JY,Kim J,Kim Y,Kim ST,Kim HS

    更新日期:2018-08-02 00:00:00

  • New concepts in the management of diffuse low-grade glioma: Proposal of a multistage and individualized therapeutic approach.

    abstract::Diffuse low-grade glioma grows, migrates along white matter tracts, and progresses to high-grade glioma. Rather than a "wait and see" policy, an aggressive attitude is now recommended, with early surgery as the first therapy. Intraoperative mapping, with maximal resection according to functional boundaries, is associa...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nou153

    authors: Duffau H,Taillandier L

    更新日期:2015-03-01 00:00:00

  • Late relapse in primary central nervous system lymphoma: clonal persistence.

    abstract::Recurrence of primary central nervous system lymphoma (PCNSL) after initial diagnosis and treatment occurs within 2 years in most patients, and relapse after 5 years is rare. We evaluated late relapse in our PCNSL population. We identified 10 patients from our database of 378 patients (268 achieved a complete response...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor014

    authors: Nayak L,Hedvat C,Rosenblum MK,Abrey LE,DeAngelis LM

    更新日期:2011-05-01 00:00:00

  • Updates in the management of brain metastases.

    abstract::The clinical management/understanding of brain metastases (BM) has changed substantially in the last 5 years, with key advances and clinical trials highlighted in this review. Several of these changes stem from improvements in systemic therapy, which have led to better systemic control and longer overall patient survi...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/now127

    authors: Arvold ND,Lee EQ,Mehta MP,Margolin K,Alexander BM,Lin NU,Anders CK,Soffietti R,Camidge DR,Vogelbaum MA,Dunn IF,Wen PY

    更新日期:2016-08-01 00:00:00

  • Diet and risk of glioma: combined analysis of 3 large prospective studies in the UK and USA.

    abstract:BACKGROUND:Available evidence on diet and glioma risk comes mainly from studies with retrospective collection of dietary data. To minimize possible differential dietary recall between those with and without glioma, we present findings from 3 large prospective studies. METHODS:Participants included 692 176 from the UK ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,meta分析

    doi:10.1093/neuonc/noz013

    authors: Kuan AS,Green J,Kitahara CM,De González AB,Key T,K Reeves G,Floud S,Balkwill A,Bradbury K,Liao LM,Freedman ND,Beral V,Sweetland S,Million Women Study, the NIH-AARP study, and the PLCO study.

    更新日期:2019-07-11 00:00:00

  • Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.

    abstract::We conducted a single-arm phase II study to evaluate the efficacy and safety of radiotherapy combined with 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine (TPDCV) chemotherapy for treating malignant astrocytoma in children and anaplastic ependymoma in patients of all ages. Between 1984 and 199...

    journal_title:Neuro-oncology

    pub_type: 临床试验,杂志文章

    doi:10.1093/neuonc/2.1.22

    authors: Levin VA,Lamborn K,Wara W,Davis R,Edwards M,Rabbitt J,Malec M,Prados MD

    更新日期:2000-01-01 00:00:00

  • Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma.

    abstract::The long-term follow-up of the RTOG 9802 trial that compared 54 Gy of radiotherapy (RT) with the same RT followed by adjuvant procarbazine, CCNU, and vincristine (PCV) chemotherapy in high-risk low-grade glioma shows a major increase in survival after adjuvant PCV chemotherapy. Median overall survival increased from 7...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nou297

    authors: van den Bent MJ

    更新日期:2014-12-01 00:00:00

  • Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.

    abstract:BACKGROUND:The colony stimulating factor 1 receptor (CSF1R) ligands, CSF1 and interleukin-34, and the KIT ligand, stem cell factor, are expressed in glioblastoma (GB). Microglia, macrophages, blood vessels, and tumor cells also express CSF1R, and depletion of the microglia reduces tumor burden and invasive capacity. PL...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1093/neuonc/nov245

    authors: Butowski N,Colman H,De Groot JF,Omuro AM,Nayak L,Wen PY,Cloughesy TF,Marimuthu A,Haidar S,Perry A,Huse J,Phillips J,West BL,Nolop KB,Hsu HH,Ligon KL,Molinaro AM,Prados M

    更新日期:2016-04-01 00:00:00

  • Brain metastases in melanoma: roles of neurotrophins.

    abstract::Brain metastasis, which occurs in 20% to 40% of all cancer patients, is an important cause of neoplastic morbidity and mortality. Successful invasion into the brain by tumor cells must include attachment to microvessel endothelial cells, penetration through the blood-brain barrier, and, of relevance, a response to bra...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1215/s115285170300067x

    authors: Denkins Y,Reiland J,Roy M,Sinnappah-Kang ND,Galjour J,Murry BP,Blust J,Aucoin R,Marchetti D

    更新日期:2004-04-01 00:00:00

  • Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.

    abstract::Antiangiogenic therapy is associated with increased radiographic responses in glioblastomas, but tumors invariably recur. Because tumor-associated macrophages have been shown to mediate escape from antiangiogenic therapy in preclinical models, we examined the role of macrophages in patients with recurrent glioblastoma...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not082

    authors: Lu-Emerson C,Snuderl M,Kirkpatrick ND,Goveia J,Davidson C,Huang Y,Riedemann L,Taylor J,Ivy P,Duda DG,Ancukiewicz M,Plotkin SR,Chi AS,Gerstner ER,Eichler AF,Dietrich J,Stemmer-Rachamimov AO,Batchelor TT,Jain RK

    更新日期:2013-08-01 00:00:00

  • Gadd45a sensitizes medulloblastoma cells to irradiation and suppresses MMP-9-mediated EMT.

    abstract::Medulloblastomas are the most common malignant tumors of the central nervous system during childhood. Radiation-induced medulloblastoma tumor recurrences are aggressive and metastatic in nature. In the present study, we demonstrate that Gadd45a expression can sensitize medulloblastoma cells to radiotherapy. We have el...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor109

    authors: Asuthkar S,Nalla AK,Gondi CS,Dinh DH,Gujrati M,Mohanam S,Rao JS

    更新日期:2011-10-01 00:00:00

  • Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).

    abstract:BACKGROUND:Diagnostic accuracy in previous studies of O-(2-[18F]-fluoroethyl)-L-tyrosine (18F-FET) PET in patients with suspected recurrent glioma may be influenced by prolonged dynamic PET acquisitions, heterogeneous populations, different non-standard-of-care therapies, and PET scans performed at different time point...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noz166

    authors: Bashir A,Mathilde Jacobsen S,Mølby Henriksen O,Broholm H,Urup T,Grunnet K,Andrée Larsen V,Møller S,Skjøth-Rasmussen J,Skovgaard Poulsen H,Law I

    更新日期:2019-12-17 00:00:00

  • The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.

    abstract:BACKGROUND:Genetic and epigenetic profiling of glioblastomas has provided a comprehensive list of altered cancer genes of which only O(6)-methylguanine-methyltransferase (MGMT) methylation is used thus far as a predictive marker in a clinical setting. We investigated the prognostic significance of genetic and epigeneti...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nou005

    authors: Molenaar RJ,Verbaan D,Lamba S,Zanon C,Jeuken JW,Boots-Sprenger SH,Wesseling P,Hulsebos TJ,Troost D,van Tilborg AA,Leenstra S,Vandertop WP,Bardelli A,van Noorden CJ,Bleeker FE

    更新日期:2014-09-01 00:00:00

  • A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy.

    abstract:BACKGROUND:Fatigue is common among glioma patients undergoing radiotherapy (RT) and impacts quality of life (QOL). We evaluated whether armodafinil, a wakefulness-promoting medication, improves fatigue in glioma patients undergoing RT. METHODS:Eligibility criteria included age ≥18 years, Karnofsky performance status ≥...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1093/neuonc/now007

    authors: Lee EQ,Muzikansky A,Drappatz J,Kesari S,Wong ET,Fadul CE,Reardon DA,Norden AD,Nayak L,Rinne ML,Alexander BM,Arvold ND,Doherty L,Stefanik J,LaFrankie D,Ruland SF,Pulverenti J,Smith KH,Gaffey SC,Hammond S,Wen PY

    更新日期:2016-06-01 00:00:00

  • BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma.

    abstract:BACKGROUND:Nonfunctioning pituitary adenoma (NFPA) and growth hormone pituitary adenoma (GHPA) are major subtypes of pituitary adenomas (PAs). The primary treatment is surgical resection. However, radical excision remains challenging, and few effective medical therapies are available. It is urgent to find novel targets...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noaa084

    authors: Shi C,Ye Z,Han J,Ye X,Lu W,Ji C,Li Z,Ma Z,Zhang Q,Zhang Y,He W,Chen Z,Cao X,Shou X,Zhou X,Wang Y,Zhang Z,Li Y,Ye H,He M,Chen H,Cheng H,Sun J,Cai J,Huang C,Ye F,Luo C,Zhou B,Ding H,Zhao Y

    更新日期:2020-08-17 00:00:00

  • DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.

    abstract::We explored the associations of aberrant DNA methylation patterns in 12 candidate genes with adult glioma subtype, patient survival, and gene expression of enhancer of zeste human homolog 2 (EZH2) and insulin-like growth factor-binding protein 2 (IGFBP2). We analyzed 154 primary glioma tumors (37 astrocytoma II and II...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq190

    authors: Zheng S,Houseman EA,Morrison Z,Wrensch MR,Patoka JS,Ramos C,Haas-Kogan DA,McBride S,Marsit CJ,Christensen BC,Nelson HH,Stokoe D,Wiemels JL,Chang SM,Prados MD,Tihan T,Vandenberg SR,Kelsey KT,Berger MS,Wiencke JK

    更新日期:2011-03-01 00:00:00

  • Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?

    abstract::Diffuse intrinsic pontine glioma (DIPG) has proven to be one of the most challenging of all pediatric cancers. Owing to a historical reticence to obtain tumor tissue for study, and based on an erroneous assumption that the biology of DIPG would mirror that of supratentorial high-grade astrocytomas, innumerable studies...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nox021

    authors: Cohen KJ,Jabado N,Grill J

    更新日期:2017-08-01 00:00:00

  • Coexpression of neuronatin splice forms promotes medulloblastoma growth.

    abstract::Medulloblastoma (MB) is the most common pediatric brain cancer. Several important developmental pathways have been implicated in MB formation, but fewer therapeutic targets have been identified. To locate frequently overexpressed genes, we performed a comprehensive gene expression survey of MB. Our comparison of 20 pr...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-038

    authors: Siu IM,Bai R,Gallia GL,Edwards JB,Tyler BM,Eberhart CG,Riggins GJ

    更新日期:2008-10-01 00:00:00

  • Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

    abstract::People with neurofibromatosis 1 (NF1) have multiple benign neurofibromas and a 10% lifetime risk of developing malignant peripheral nerve sheath tumors (MPNSTs). Most MPNSTs develop from benign plexiform neurofibromas, so the burden of benign tumors may be a risk factor for developing MPNST. We studied 13 NF1 patients...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-011

    authors: Mautner VF,Asuagbor FA,Dombi E,Fünsterer C,Kluwe L,Wenzel R,Widemann BC,Friedman JM

    更新日期:2008-08-01 00:00:00

  • A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma.

    abstract::The purpose of this study was to evaluate the activity of single-agent bevacizumab in patients with recurrent anaplastic glioma and assess correlative advanced imaging parameters. Patients with recurrent anaplastic glioma were treated with bevacizumab 10 mg/kg every 2 weeks. Complete patient evaluations were repeated ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor091

    authors: Kreisl TN,Zhang W,Odia Y,Shih JH,Butman JA,Hammoud D,Iwamoto FM,Sul J,Fine HA

    更新日期:2011-10-01 00:00:00

  • Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

    abstract::Peripheral neuropathies induced by chemotherapy (CIPN) are an increasingly frequent problem. Contrary to hematologic adverse effects, which can be treated with hematopoetic growth factors, neither prophylaxis nor specific treatment is available, and only symptomatic treatment can be offered. Neurotoxic drugs are becom...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nos203

    authors: Grisold W,Cavaletti G,Windebank AJ

    更新日期:2012-09-01 00:00:00